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Optimal functioning of the immune system is crucial to human health, and nutrition is one of the major exogenous factors modulating
different aspects of immune function. Currently, no single marker is available to predict the effect of a dietary intervention on different
aspects of immune function. To provide further guidance on the assessment and interpretation of the modulation of immune functions
due to nutrition in the general population, International Life Sciences Institute Europe commissioned a group of experts from academia,
government and the food industry to prepare a guidance document. A draft of this paper was refined at a workshop involving additional
experts. First, the expert group defined criteria to evaluate the usefulness of immune function markers. Over seventy-five markers were
scored within the context of three distinct immune system functions: defence against pathogens; avoidance or mitigation of allergy; control
of low-grade (metabolic) inflammation. The most useful markers were subsequently classified depending on whether they by themselves
signify clinical relevance and/or involvement of immune function. Next, five theoretical scenarios were drafted describing potential
changes in the values of markers compared with a relevant reference range. Finally, all elements were combined, providing a framework
to aid the design and interpretation of studies assessing the effects of nutrition on immune function. This stepwise approach offers a clear
rationale for selecting markers for future trials and provides a framework for the interpretation of outcomes. A similar stepwise approach
may also be useful to rationalise the selection and interpretation of markers for other physiological processes critical to the maintenance of
health and well-being.
The overall aim of this article is to provide further guidance for
the assessment and interpretation of immune modulation by
nutrition in the general population. To this end, the European
Branch of the International Life Sciences Institute (ILSI) estab-
lished a group of experts from academia, government and the
food industry to agree upon criteria to evaluate the usefulness
of immune function markers in a structured manner. Over
seventy-five markers were scored and evaluated within the
context of three distinct domains of immune function: defence
against pathogens; avoidance or mitigation of allergy; control
of low-grade inflammation mainly focusing on metabolic
inflammation. Other aspects of immune function such as auto-
immunity and surveillance against tumours were not included
at this stage. The most useful markers were classified depend-
ing on whether they by themselves demonstrate clinical
relevance and/or involvement of immune function. In
addition, five theoretical scenarios were drafted describing
potential changes in the values of markers compared with a
relevant reference range. These include (significant) modu-
lation within the reference range (a very common scenario
for modulation due to nutrition), modulation from outside
the reference range back into the range, modulation from
within the reference range out of the range, prevention of
modulation induced by other factors, and modulation from a
less favourable range to the reference range of a comparator
group with a more desired immune function (e.g. from
bottle-fed to breast-fed infants). Finally, the expert group com-
bined all of the above-mentioned information, providing
a framework to aid the design and interpretation of studies
assessing the effects of nutrition on immune function. An
early draft of this report was discussed with a wider group
of experts at a workshop held in Nice, France, 16–17 April
2012. Additional information about the workshop discussions
and participants is available on the ILSI Europe website
(http://www.ilsi.org/Europe/Pages/HomePage.aspx).
The main function of the immune system is to help maintain
homeostasis by providing protection against infections. On the
other hand, inappropriate or improperly controlled immune
functions contribute to pathophysiological processes such as
allergic manifestations and chronic inflammatory responses.
Development and maintenance of a normal immune system
are thus essential for a healthy and active life. Functioning
of the immune system is influenced by a variety of inherited,
environmental, behavioural, social and individual factors(1).
Therefore, it is no surprise that solutions to help develop,
restore or optimise immune functions are much sought after
by scientists, consumers and industry alike.
One of the major modifiable factors affecting immune
function is nutrition (the primary factor being vaccination);
undernutrition is often related to decreased immune function,
whereas overnutrition and obesity can contribute to chronic
low-grade inflammatory changes. Whole diets, individual
nutrients and food components such as phytochemicals,
prebiotics and probiotics have all been shown to influence
distinct aspects of the immune system. These effects have
been reviewed extensively in a number of recent papers(2–21).
Several other papers have provided some guidance on how
best to assess specific immune functions and which confound-
ing factors and methodological aspects to consider(1,18,22–28).
Moreover, the European Food Safety Authority panel on dietetic
products, nutrition and allergies has recently issued a
guidance document on the scientific requirements for the sub-
stantiation of health claims related to gut and immune
function(29). This document offers an excellent starting point
for the assessment and interpretation of immune modulation
by nutrition. However, some critical elements are still missing,
and especially when focusing on the assessment and optimis-
ation of immune function in the general population, some ques-
tions remain largely unanswered. These include the following:
(1) How can ‘optimal immune function(s)’ be identified and
characterised? (2) Which markers are most informative to
describe (optimal) immune function(s)? (3) How can changes
in the values of these markers be interpreted? (a) Can immune
function(s) in a general population be optimised? (b) How to
assess improved immune function(s)? (c) How to identify risk
associated with the modulation of immune function(s)?
This article aims to provide some further guidance on these
aspects by providing criteria for the selection of immune func-
tion markers, ranked lists of markers that best describe the
(modulation of) specific immune functions in the general
population, reference to normal values and ranges established
in laboratory medicine and daily clinical practice for selected
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markers, and rational approaches for the design of studies,
selection of markers and interpretation of changes observed
in these markers due to exogenous factors such as nutrition.
Paradigm relating immune function to health
The basic paradigm of the relationship between immune func-
tion and health is illustrated in Fig. 1. Regardless of the marker
or assay used, immune functions vary between subjects and
they fluctuate over time within a subject. In a healthy popu-
lation, these fluctuations define the boundaries of a ‘normal
range’, and immune function(s) within this ‘homeodynamic
bandwidth’ are postulated to support the maintenance of
‘optimal health’. Genetic make-up and past experiences con-
tribute to differences between subjects, and environmental
or lifestyle-associated factors can temporarily or permanently
move specific immune function(s) outside these ranges, thus
failing to support optimal health. If this is sustained or
becomes more extreme, it may contribute to pathogenic
processes and modify disease risk. Within this paradigm,
optimising immune function encompasses the return of such
function(s) back into the normal range and/or strengthening
of the resilience of the function(s), thus reducing the ampli-
tude of fluctuations and reinforcing the homeodynamic
regulation within the optimal range(2,30). Consequently, at
times, it may be beneficial to down-regulate hyperactive
immune functions or up-regulate hypoactive immune func-
tions or to strengthen the resilience of immune functions to
respond to external ‘stressors’.
Brief overview of major immune functions
The immune system helps to maintain homeostasis by mount-
ing non-specific innate and specific adaptive responses against
potentially pathogenic micro-organisms. At the same time, the
immune system should tolerate self-antigens and innocuous
non-self-antigens and allergens as uncontrolled or inappropri-
ate responses to such antigens contribute to the pathogenic
processes underlying various non-communicable diseases.
Inappropriate or exaggerated immune responses to allergens
lead to allergic manifestations such as allergic rhinitis (hay
fever), allergic asthma, atopic dermatitis (eczema) and food
allergy. Sustained responses to persistent antigens, such as
autoantigens or those that are derived from commensal
micro-organisms, lead to tissue remodelling and loss of func-
tion of the affected tissue and contribute to the symptoms of
chronic inflammatory diseases such as rheumatoid arthritis,
inflammatory bowel disease and psoriasis(2,31). More recently,
it has also become apparent that metabolic stresses (e.g. in
visceral adipocytes of obese subjects) trigger low-grade
asymptomatic inflammatory responses, which contribute to
the comorbidity of metabolic disorders(32,33).
These different aspects of immune function are highly rel-
evant in the general population, affecting the maintenance
of health and vitality. Immune function markers are, therefore,
considered within the context of the following distinct
physiological function domains of the immune system:
defence against pathogens; avoidance or mitigation of allergy;
reduction of asymptomatic low-grade metabolic inflammation.
Defence against pathogens relates to the physiological func-
tion of the immune system to deal with (common) pathogens
such that the infection does not establish itself, or if it does,
then with no or minimal symptoms. Avoidance or mitigation
of allergy relates to the ability of the immune system to toler-
ate potentially allergenic substances without symptoms of
allergy. The beneficial effects of nutrition on this activity
could thus, in theory, lead to reduced sensitisation to an
allergen or mitigation of the severity of allergic responses to
non-food-related allergens such as respiratory or contact aller-
gens and so are not necessarily restricted to food allergy.
Reduction of asymptomatic low-grade inflammation relates
to the ability of the immune system to control low-grade
inflammatory responses that are triggered by metabolic stres-
ses and that, if improperly controlled, become chronic and
contribute to the pathophysiology of various diseases.
Ageing
Diet
Smoking
Alcohol
(Lack of) exercise
Sleep deprivation
Hygiene
...
‘Danger’
Pathogens, insults,
allergens, m
etabolic stress...
Hypoactive
Hyperactive
Chronic inflammation allergies
Impaired infection resistance
‘Optimal immune
function’
‘Optimal health’
Fig. 1. Illustration of the general paradigm postulating that fluctuations within the boundaries of a normal range support the maintenance of optimal health. Regard-
less of the marker or assay used, immune functions vary between subjects and they fluctuate within subjects over time ( ), although apparently within some
normal limits (green zone) that may be individually defined. Certain (combinations of) factors can drive immune function(s) to a state of hypo- or hyperactivity
( ). The objective of a (nutritional) intervention is to restore functions to the normal range ( ) and/or to strengthen the resilience of these function(s), redu-
cing the amplitude of fluctuations and thus reinforcing the homeodynamic regulation within the normal range. Adapted from Hamer et al.(30).
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To exert its functions, the immune system deploys a range
of structural, cellular and molecular components. A wide
variety of methods and markers are being used to measure
the magnitude of variation of these immune functions. Such
markers range from the assessment of clinical symptoms
and integrated responses to particular in vivo challenges
and ex vivo assessment of isolated functions of the immune
system to more basic enumeration of a particular (sub)type
of cell or measurement of the concentrations of specific factors
without any defined challenge to the system. Building on a
previous publication(1), we have classified the markers from
the most integrated/physiologically relevant to the most
isolated/mechanistically insightful as illustrated in Fig. 2.
It is acknowledged that new technologies, such as
genomics, proteomics and so forth, are continuously being
developed. Such techniques may, in the future, provide new
biomarkers and also more insight into relevant intracellular
responses. Future evaluation of such new biomarkers,
however, can follow the same criteria as for the current
biomarkers.
The following definitions are used in this work:
Symptom: sensation or change in bodily function or
appearance experienced by a person that suggests a disorder
or pathology (e.g. runny nose as a symptom of a respira-
tory infection or rhinitis and watery stool as a symptom of
diarrhoea).
In vivo response: integrated response to a (standardised)
in vivo challenge (e.g. response to vaccination, prick and
patch tests or oral provocation test).
Ex vivo response: (nutritional) intervention or comparison
occurring in vivo; cells or blood isolated from participants in
a study is assayed for functionality using a defined in vitro
challenge (e.g. phagocytosis, natural killer (NK) cell activity
or production of cytokines by ex vivo stimulated peripheral
blood mononuclear cells or whole blood).
In vitro response: (nutritional) intervention or comparison
occurring in vitro; cells or blood isolated from subjects not
participating in a study is exposed in vitro to the compounds,
nutrients and so forth to be compared and is subsequently
assayed for functionality using a defined in vitro challenge.
This use of functional assays is intended not as a biomarker
but rather as a tool for screening or mechanistic studies.
This approach is outside the scope of the current activity.
Basal markers: cellular or molecular components of the
immune system that are measured without a defined pre-
ceding challenge (e.g. cell types or cytokines). Not to be
confused with the basal level (which is the actual value).
Methodological and technical considerations
Study design, randomisation and selection of appropriate con-
trol groups are critically important aspects when designing
human studies for any outcome. Generic and more specific
considerations for studies focusing on the effects of nutrition
on immune function have been described in detail in earlier
publications(1,23–25). The effects of nutrition are potentially
important in the longer term, but are typically modest and
often difficult to observe in the short term. To assess these
modest effects, it is important to carefully consider other
factors known to influence immune function as these may
otherwise obscure the effects of nutrition. Such confounders
include stress(34), age(35,36), sex(37), ethnicity, physical fit-
ness(18), circadian(38,39) and seasonal(40) influences, and sleep
deprivation(41). Using carefully selected procedures for
randomisation and clear criteria for (non)inclusion(42), these
confounders should be controlled for as much as possible.
In some cases, they may also be used to select representative
at-risk subpopulations to increase the sensitivity of the study.
Examples of this include the selection of children from atopic
parents(43), children in day-care centres exposed to a high
infection load(44), people complying with specific exercise
regimens(18), shift workers(45), people suffering from irritable
bowel syndrome(46) or food intolerances(47,48), people with a
BMI above a particular threshold(49), elderly individuals
above a particular age(50) and so forth. Although this can
greatly increase the sensitivity of the study to detect modu-
lation by nutrition, care should be taken that the selected sub-
population is still sufficiently representative of the general
population to allow meaningful extrapolation. For the
purpose of the current activity, we focus on the selection of
markers of immune functions to assess the effects of nutrition
in the general population assuming the use of properly con-
trolled, well-designed observation or intervention studies
that take all of these critical elements into account.
When selecting markers to assess effects on immune
function, it is important to realise that the identification, devel-
opment and (clinical) validation of markers are mostly done in
the context of diseases. Whereas the relevance of particular
markers for the diagnosis or prognosis of specific diseases
may be well established, their relevance in a general popu-
lation is typically less clear as very few prognostic studies
have carefully assessed the predictive value of these markers
Clinical relevance
Clinical symptoms
In vivo immune response
B
asal m
arkers
(num
ber or concentration of cells or factors w
ithout stim
ulation)
Ex vivo immune functions
In vitro, isolated cells, molecules, etc.
Mechanism and hypothesis generation
Isolated functions
Integrated response
Fig. 2. Graphical representation indicating the classification of immune func-
tion markers from the most integrated/physiologically relevant to the most
isolated/mechanistically insightful, with the basal markers being positioned
on the side as they do not indicate a function by themselves, but aid in the
interpretation of the functional markers.
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for maintenance of health. Moreover, in the context of disease,
markers are commonly used to determine the diagnosis or
prognosis for individual patients. Based on a comparison of
a patient’s marker with a defined normal or reference range,
conclusions are drawn for the individual patient. In contrast,
in the context of nutritional effects in the general population,
immune function markers are used to establish meaningful
changes that occur at the group level. Typically, average
(changes in) values of markers in one group are compared
with (changes in) the values of markers in a control or
reference group. This can be done observationally to assess
associations between particular nutritional traits and immune
functions or experimentally by applying a specific nutritional
intervention in one of two groups to assess the impact of
that intervention. In both cases, conclusions are drawn regard-
ing the effect of the nutritional difference on immune function
at the group level. Despite these differences between the use
and interpretation of markers in the context of disease or in
the context of the general population, essentially similar cri-
teria apply when determining the usefulness of individual
markers, although the relative weight of the individual criteria
may be somewhat different.
In all cases, it should be clear as to what marker is measured
and the assay used should measure it reliably; procedures
and assays should be properly standardised and analytically
validated. This includes the use of standardised operating
procedures, including details of sampling, transport, storage
and measurement of the analytes. Many analytes are sensitive
to sampling conditions such as time during the day (circadian
rhythm), fasting v. non-fasting, subject anxiety or stress level
and even whether a blood sample is taken using a vene-
puncture or an indwelling catheter. Conditions for sample
processing, transport and storage should, therefore, be clearly
established and standardised, and the laboratory measurement
should be analytically validated. This includes specificity,
sensitivity, limit of detection, precision, robustness and linear-
ity involving proper quality control and international gold
standards if available. Several excellent papers have provided
more specific information on the critical aspects of analytical
validation and general laboratory quality management systems
(e.g. EN ISO 15 189 and EN ISO 17 025) or on those described
in the good clinical laboratory practice guidelines(51–55).
Some immune function markers such as C-reactive protein
(CRP), differential cell counts or lymphocyte subset
distributions are commonly used in clinical settings; for these
properly validated procedures, assays and defined normal
ranges and threshold values have been established (see, for
instance, http://labtestsonline.org/). An example of reference
ranges for lymphocyte subsets in different age groups has
been given in several publications(56–59). However, most of
these markers are basal markers involving the enumeration of
cells or factors in a sample without controlled experimental
stimulation to assess a specific functional response. Such
markers can aid the interpretation of more functional assays,
but by themselves have limited value in nutrition studies, as
they are rather insensitive to detect a modest modulation
due to nutrition and are difficult to interpret in the general
population. Unfortunately, more useful markers involving a
functional response to a challenge such as in vivo challenge
tests and ex vivo cellular function assays are much less stan-
dardised, have not been validated to the same extent and
results can generally not be compared very well between
laboratories. Moreover, assays and procedures involved are
frequently tailored, for instance, by using suboptimal stimu-
lation conditions (suboptimal concentration or incubation
time) in ex vivo functional cell assays or by assessing
responses after a suboptimal vaccination protocol (low level
of adjuvant, low vaccine dose, only fraction of a multiple-
dose antigen given, and assessment of the response during
its early exponential phase). Although these modifications
make good sense to increase the sensitivity and dynamic
range to detect modulatory effects by avoiding saturation of
the responses, they have led to a broad variety in protocols
being used, many of which are not yet sufficiently standar-
dised or validated to allow comparisons between different
laboratories. There is a clear need for further standardisation
and validation of these markers using protocols optimised to
assess (alterations in) immune function in the general popu-
lation. This should include further standardisation, analytical
validation and ring testing between sites. Once this has been
established, it will become more feasible to include such mar-
kers in prospective cohorts aiming to establish normal ranges
and threshold values as well as their predictive values in the
general population.
Normal ranges and thresholds are commonly used in clini-
cal settings to interpret (changes in) markers of individual
patients. Despite the different contexts and the limitations
indicated above, essentially similar principles may be applied
to devise a rational framework to aid the interpretation of
nutritional effects on immune function at the group level in
the general population. In the absence of more generically
applicable normal ranges, (changes in) immune function mar-
kers are commonly compared with the following: the value
of the markers in the same subjects before the intervention,
the values of the markers in an appropriate control group
matched for the most relevant criteria (age, sex, body
weight, etc.) within the same study or combinations of the
above (e.g. comparing the change within subjects between
groups).
The strengths and limitations of these approaches have
been discussed previously, and selection of the most appropri-
ate reference group needs to be done on a case-by-case
basis(1,18,22–25,27). Importantly, for markers without established
normal ranges and threshold values, comparison with the
reference range obtained in an appropriate control group
can be used as the basis for the interpretation of effects.
This can be done by using statistical significance after
appropriate analysis to determine the threshold for relevance
as discussed in more detail below.
Criteria to select immune function markers
As has been indicated above, a wide variety of markers can be
used to assess different aspects of the immune system, and
multiple assays based on diverse technical principles are
often available. We aimed to define generic criteria to select
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the most useful markers. It is acknowledged that markers may
respond in clusters or that ratios of different markers may be
calculated. Such marker clusters or ratios have not been
included (except for an example of an immune risk profile
defined in elderly individuals) in order not to further increase
the size of the tables. The reader can, however, compile such
composite markers and assess their usefulness following the
criteria set out below.
The criteria and scoring system used are based on the work
by Albers et al.(1) involving criteria that cover clinical rel-
evance, biological sensitivity, feasibility and practical aspects
for use in nutrition studies. Scores range from 0 to þþþ ,
where þþþ is the highest score for the most solid evidence.
More details on the standardised scaling used for each of these
criteria are provided in Table 1.
Because the analysis focuses on the evaluation and ranking
of markers and not on assays used to measure these markers,
criteria for analytical validation were not included. Instead, it
was assumed that markers are assessed using the optimal
assay, according to the relevant standards discussed in the
following sections on methodological and technical consider-
ations and the selection and prioritisation of markers. In
addition, whether a marker has previously been shown to
be sensitive to nutrition was not included as a criterion
because this is severely confounded by what has been tried
and does not help to assess the intrinsic usefulness of
a marker to define the (modulation) of immune function.
However, when designing a specific study, it would be wise
to consider the possibility that a particular marker is modu-
lated by that particular nutritional modification (e.g. based
on existing data or on mechanistic insights). The criteria
that were selected to evaluate the generic usefulness of markers
can be grouped into three clusters: clinical relevance; biological
sensitivity; feasibility. In addition, practical aspects including
costs and logistic implications were scored because these
are important aspects to know; however, as these are non-
scientific arguments that may weigh very differently in different
settings, these practicalities were not included in the integrative
assessment of the overall usefulness of the markers.
Clinical relevance
Clinical relevance is the weight that one would give to a
specific biomarker to reflect an immune system-mediated
clinically detectable health status in the general population
Differentially expressed in normal and high-risk individuals.
This criterion should be linked to the different functional
domains (defence against pathogens, allergens and inflam-
mation). Scores given in Tables 2 and 3 are for the functional
domain for which the marker has most relevance. While the
level of a given marker may be important, the way it is
measured is also relevant because the evaluation can be
made based on single measurements as well as the kinetics
of a marker response. Markers without any known or antici-
pated relevance for the general population are outside the
scope of this article (e.g. specific leucocyte tumour markers).
Correlates with relevant clinical endpoint. Note that
correlation does not necessarily imply causality. Markers
without a known correlation with a given immunological
function/status for the general population are outside the
scope of this work for further evaluation.
Experimentally linked to causal pathway. The markers
rating the highest would be those for which proof of causality
has been clearly established using human data.
Biological sensitivity. Biological sensitivity is the level to
which the marker is influenced by and linked to the biological
process. This factor is highly influenced by the ‘normal’ inter-
and intra-subject variation as well as by the amplitude of the
studied effect. A distinction is made between explainable vari-
ation and unexplainable variation; it is assumed that it would
be possible to (partially) correct for the former.
Reasonable within-subject variation. The higher the
within-subject variation, the larger the number of subjects
required to observe an effect within a subject and the lower
the score. As many immune function markers have (substan-
tially) lower intra- than inter-subject variation, comparison of
changes within subjects between groups (instead of compar-
ing individual measurements per subject) often helps to
increase sensitivity to detect effects.
Reasonable/explainable between-subject variation. The
higher the between-subject variation, the larger the number
of subjects required to observe an effect between groups
and the lower the score.
Feasibility. Feasibility pertains to how feasible/practical it
is to measure the biomarker.
Technical feasibility. The sensitivity of the assay available
should be sufficient to detect the effect. The assay can be used
repeatedly if needed (e.g. no saturation of response as with
vaccination). The criteria include aspects such as stability of
the marker, storage of the sample (storage possible v. need
to work with fresh material), limitations of sample transpor-
tation, level of preanalytical processing and so forth.
Robustness. This criterion makes a general assessment of
the precision and accuracy of the best assay available to
measure a given marker. This reflects the level of variation
between assays performed by different people, with different
instruments (if relevant) or in different laboratories as well as
the degree of uncertainty about the result obtained. The best
score is given to a standardised assay with an acceptable CV
that enables the detection of the expected effect size. This is
reflected by approval or non-approval by regulatory auth-
orities and/or wide distribution. Note that an assay only
used in a single research laboratory can be very robust, but
strong evidence would not be accessible to prove so.
Practicality. Practicality pertains to how practically feas-
ible it is to measure the biomarker in nutrition studies.
Although cost and logistic aspects involved in the assessment
of particular markers affect the feasibility to include markers in
particular studies, these aspects were not taken into consider-
ation when determining the overall usefulness of a marker,
which was based on scientific criteria. As these practical
aspects are nonetheless very important, a score is provided
for information based on aspects such as the number of
visits the subject is required to make, the availability and
cost of the assay, the degree of expertise needed to perform
the assay and so forth.
Immune modulation by nutrition S7
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114513001505
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:47:45, subject to the Cambridge Core terms of use, available at
Table 1. Criteria for the evaluation of markers
Clinical relevance Biological sensitivity Feasibility
Levels
Differentially
expressed
Correlates with
clinical endpoint
Linked to causal
pathway
Within-subject
variation
Between-subject
variation Technical Robustness Practicality
Proven
(þþþ )
Reproducibly
proven association
of differential
expression with
differential risk
Generally accepted
as a risk factor
(correlation with
onset/resolution of
the clinical endpoint)
Proven explanation
backed by human
data
Minimal variation and
relevant effects highly
superior to variation:
effects likely to be
observed between
groups of tens of
people
Minimal variation and
relevant effects highly
superior to variation:
effects likely to be
observed between
groups of tens of
people
Marker is stable and
validated and highly
available assay and
can easily be done
repeatedly with high
throughput (e.g. CRP)
Approved diagnos-
tic test available
(IVD; e.g. CE
marked or FDA
approved)
Minimally invasive,
done at bedside
(a general practitioner
can do it) (e.g. symp-
toms, faeces, urine
and saliva) – single
interaction with the
subject
Strong
(þþ )
Direct evidence
linking differential
response to
differential risk
(e.g. vaccination)
Described as a
cause and effect
relationship, but
not (yet) generally
accepted as a risk
factor, needs more
studies or not
specific
Plausible mechan-
istic hypothesis
with some human
data
High variation explain-
able (e.g. circadian
cycle) and possible to
correct it and relevant
effects reproducibly
superior to variation:
effects likely to be
observed between
groups of fifties to
hundreds of people
High variation explain-
able (e.g. age, sex,
BMI, ethnicity and
genotype) and poss-
ible to correct it with
stratification and
relevant effects repro-
ducibly superior to
variation: effects likely
to be observed
between groups of
fifties to hundreds
of people
Sample can easily
be made stable and
limited processing
(e.g. preparation of
PBMC), or sample
can be refrigerated
for a limited time
(e.g. ELISA of
cytokines)
Service commer-
cially available in
accredited labora-
tories (e.g. LDT
through CLIA
laboratories in
the USA)
Somewhat invasive
(blood sample) – may
require several inter-
actions with the
subject (vaccination,
skin prick test, etc.)
and sample sent to
a laboratory
Medium
(þ)
Indirect evidence
linking a change in
function to a change
in risk
Body of evidence
suggesting corre-
lation, but cause and
effect not established
Plausible mecha-
nistic hypothesis
backed by animal
data
High variation explain-
able (e.g. circadian
cycle) and possible to
correct it and relevant
effects reproducibly
close to variation:
effects may be
observed between
groups of fifties to
hundreds of people
High variation explain-
able (e.g. age, sex,
BMI, ethnicity and
genotype) and poss-
ible to correct it with
stratification and rel-
evant effects reprodu-
cibly close to
variation: effects may
be observed between
groups of fifties to
hundreds of people
Sample needs to be
frozen, or assay can
only be done once
(e.g. response to
vaccination)
Commercially
available RUO kits
Expert and/or expens-
ive material needed
(MRI, X-ray and
routine flow
cytometry)
Low (0) Plausible hypothesis
with supporting
animal data
Plausible hypothesis,
in use as an explora-
tory marker, but no
substantial body of
evidence (yet)
Plausible mechan-
istic hypothesis
backed only by
in vitro data
High and unexplained
variation in a short
time span and rel-
evant effects likely to
be observed between
groups of thousands
of people
High and unexplained
variation in a very
short time span and
relevant effects likely
to be observed
between groups of
thousands of people
Sample needs to be
extensively processed
or stored at (808C
or analysed fast
(e.g. in-line functional
assays)
No commercially
available LDT
locally (in-house)
and validated/pub-
lished protocols
available
Requires an expert
outside the laboratory,
medical surveillance
and/or specific equip-
ment (e.g. colono-
scopy, biopsies,
investigative flow
cytometry and chemi-
cal sensitisation)
CRP, C-reactive protein; IVD, in vitro diagnostics; CE Mark, a mandatory conformity mark for products placed on the market in the European Economic Area; FDA, US Food and Drug Administration; PBMC, peripheral blood mono-
nuclear cells; LDT, laboratory-developed tests; CLIA, Clinical Laboratory Improvement Amendments; RUO, research use only.
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Selection and prioritisation of markers
Over seventy-five commonly used or recommended markers
were evaluated according to the criteria specified in Table 1.
For these markers, Tables 2 and 3 indicate the following: (1)
whether a marker has relevance for the general population
or is mainly relevant for specific subpopulations; (2) scores
given for each of the defined criteria detailed in Table 1, all
scored from 0 to þþþ ; (3) an overall marker score indicating
the subjective expert judgement on the usefulness of each
marker based on the weighed evaluation of scores for individ-
ual criteria (A, not very useful; B, low suitability; BB, medium
suitability; and BBB, high suitability); (4) practicalities associ-
ated with the assessment of a marker (need for expensive,
specialised equipment, need for repeated assessments, etc.);
(5) plausible link to the three domains of immune function
(scored not relevant (0) to most relevant (þþþ) for each
domain), including defence against pathogens, avoidance or
mitigation of allergy, and control of low-grade metabolic
inflammation; (6) references illustrating the use of a particular
marker in nutrition studies.
Table 2 summarises the clinical symptoms and in vivo mar-
kers for the three domains of physiological immune function.
Symptoms of conditions that are relatively common in the
general population are sometimes used as indirect markers
of immune function. Clearly, they provide the most clinically
relevant indication of intervention effects, but it is important
to realise that symptoms by themselves may not necessarily
indicate altered immune function because other non-
immune system-mediated mechanisms may be responsible
for the changes in symptom scores. As self-assessment has
been criticised for being subjective, unspecific and therefore
unreliable, it is important that symptoms be scored by
qualified persons blinded to the intervention. Alternatively,
properly validated questionnaires can be used, which may
be complemented by confirmation of symptoms by qualified
persons. Examples of validated questionnaires include the
Jackson(60–62) and Wisconsin(63–65) scores for respiratory
infections, the Vesikari(66) or WHO(67) scores for diarrhoea,
SCORing Atopic Dermatitis (SCORAD)(68–70) for eczema,
Allergic Rhinitis and its Impact on Asthma(71) for rhinitis,
Asthma Control Test(72) or Test for Respiratory and Asthma
Control in Kids(73) for asthma, and Mini Nutrition Surveys for
the health and well-being of elderly individuals(74,75). Because
symptoms of naturally occurring infections or allergies
develop at unpredictable moments and relatively infrequently
in the general population, they are only useful as markers in
studies of sufficient size and duration. To some extent, this
can be addressed by performing the study in periods with
increased incidence (e.g. winter for respiratory infections
and spring/summer for hay fever) or by selecting (sub)popu-
lations more prone to develop symptoms such as groups with
a higher prevalence of getting infected (e.g. children in devel-
oping regions, elderly individuals in nursing homes, children
attending day-care centres, shift workers, etc.) or populations
predisposed to develop allergies (e.g. children of atopic
parents). However, in such cases, it is important to evaluate
to what extent the outcome of the study can still be extrapo-
lated to the general population. Contrary to (common) infec-
tions and allergies, inflammatory responses do not lead to
symptoms that can be usefully assessed in the general popu-
lation. Low-grade metabolic inflammation associated with
(visceral) adiposity or inflammation linked to ageing is quite
common, but by itself does not lead to overt symptoms.
Instead of waiting for symptoms to occur due to natural
causes, they can also be elicited as part of the study design
using an experimental infection with (attenuated) pathogens
or a provocation with allergens. For instance, studies have
successfully assessed symptoms elicited by an experimental
infection with rhinoviruses(76–78), Shigella (79), respiratory
syncytial virus(80) or enterotoxigenic Escherichia coli (81). Like-
wise, acute symptoms elicited by ingestion(82,83) or nasal
application(84,85) of allergens such as those used for the diag-
nosis and monitoring of allergy can also be used as markers in
nutrition studies, be it that they will only result in symptoms in
subjects who are allergic to a particular allergen. Importantly,
unlike naturally occurring symptoms in which the time of
occurrence and the exact eliciting trigger are unknown, exper-
imental challenges make it feasible to combine the assessment
of symptoms with that of the markers of contributing immune
function(s) and even the kinetics of responses can be moni-
tored to help establish cause–effect relations.
Although it is scientifically very attractive to use experimen-
tal challenges leading to symptoms that can be associated with
changes in specific immune functions, such an approach
clearly has ethical constraints. In particular studies, it may be
more feasible to use somewhat weaker or more localised
challenges that do not lead to symptoms but still modulate
the relevant immune functions. Such in vivo markers of
immune function include responses to vaccination (as a
model for the response to an infection), to dermal recall antigen
application (as a model for immune surveillance of the skin), to
(local) allergen challenge (as a model for allergic responsive-
ness) and to transient inflammatory responses triggered by a
pro-inflammatory challenge (as a model for the resilience of
inflammatory control).
Vaccines trigger in vivo immune responses almost without
eliciting symptoms of disease that would result from inocu-
lation with live virulent pathogens. Specific immune responses
to vaccines that are part of a national vaccination schedule can
be used as in vivo indicators of the integrated immune
response to these vaccines. Alternatively, one or more selected
vaccinations can be integrated into the design of a study.
Selection or stratification of subjects based on pre-existing
responsiveness and careful consideration of the vaccine used
(e.g. oral v. injected, type and dose of adjuvant, primary v.
booster, single v. multiple dose, and T-cell independent v.
T-cell dependent) and time point(s) selected to assess the
response (early exponential phase v. later plateau phase, v.
detailed analysis of the kinetics of the response) in relation
to the postulated mechanism of action and the population in
which the study will be performed can help to increase the
sensitivity to detect the modulation of responsiveness due to
nutrition. Seroprotection is defined as an antibody titre
superior to an established threshold for clinical protection
specific to each vaccine(86,87). Seroconversion is defined as a
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Table 2. Clinical symptoms and in vivo immune function markers
Clinical relevance* Biological sensitivity* Feasibility* Plausibly linked to†
Functions Markers
Mainly
relevant for
specific
subpopulations
Differentially
expressed
Correlates
with
clinical
endpoint
Linked to
causal
pathway
Within-
subject
variation
Between-
subject
variation Technical Robustness
Arbitrary
marker
score‡ Practicality* Pathogens Allergy Inflammation
Example
references
Defence against
natural infec-
tions§
Incidence of symptoms No þþþ þþþ þþþ þ þ þþþ þþþ BBB þþ þþþ 0 þþ /0k 120–132
Duration of symptoms No þþþ þþþ þþþ þ þ þþ þþ BBB þþ þþþ 0 þþ /0k
Severity of symptoms No þþþ þþþ þþþ þ þ þþþ þþþ BBB þþ þþþ 0 þþ /0k
Pathogen load{ No þþ þþ þþþ þ þ þ þ BB þ þþþ 0 0
Pathogen-specific
immune response{
No þþ þ þþ NA þ 0 0 B 0 þþþ 0 þþ /0k
Defence against
experimental
infection**
Incidence of symptoms No þþþ þþ þþþ NA þ þ þþþ BBB 0 þþþ 0 0 80,81,133–135
Duration of symptoms No þþþ þþ þþþ NA þ þ þþ BBB 0 þþþ 0 0
Severity of symptoms No þþ þþ þþþ NA þ þ þþþ BBB 0 þþþ 0 0
Pathogen load No þþþ þþþ þþþ NA þ þ þþ BBB þ þþþ 0 0
Pathogen-specific
immune response
No þþþ þþ þþþ NA þ þ þ BBB þþ þþþ 0 0
Response to
vacci-
nation††
Seroprotection No þþþ þþþ þþþ NA þ þ þþþ BBB þþ þþþ 0 0 136–141
Seroconversion No þþþ þþþ þþþ NA þ þ þþþ BBB þþ þþþ 0 0
Vaccine-specific
antibodies (concen-
tration and titre)
No þþ þþ þþ NA þ þ þþþ BBB þþ þþþ 0 0
Vaccine-specific T-cell
responsiveness
No þþ þ þþ NA þ þ þþþ BBB þþ þþþ 0 0
Immunosurveil-
lance of the
skin
DTH response to local
recall antigen
application
Yes (sensitised) þþ þþ þþþ þ þ þþ þþ BB þþ þþþ þþ þþ 137,142–146
Experimental CHS No þþ þþ þþ þ þ þþ 0 BB 0 þþ þþþ þþ 90,91
Migration of
Langerhans cells
No þ 0 þ þ þ þ 0 B 0 þþ þþþ 0 92,147
GI barrier
function‡‡
Sugar permeability No þ þþ þ þ þ þþ 0 B þþ þþþ þ þþþ 122,148–152
Bacterial translocation No þ þþ þ þ þ þ 0 B 0 þþþ þþ þþþ 153–155
Serum endotoxins No þ þþ þ þ þ þþ þ B þ þþþ þ þþþ 154,156
Tolerance to
allergens
Incidence of symptoms Yes (allergic
subjects)
þþ þþþ þþþ þ þ þþ 0 BBB þþ 0 þþþ þ 68,69,
71–73,98,
157–163
Duration of symptoms Yes (allergic
subjects)
þ 0 þ þ þ þ þ B 0 0 þþþ þ
Severity of symptoms
(e.g. peak flow,
SCORAD, ARIA,
Asthma Control Test
(ACT) and TRACK)
Yes (allergic
subjects)
þþþ þþþ þþþ þ þ þþþ þ BBB þþþ 0 þþþ þ
Response to an
allergen
challenge
Prick test Yes (allergic
subjects)
þþþ þþþ þþþ þ þ þþ þþ BBB þþ 0 þþþ 0 164–167
Contact hypersensitivi-
ty/patch test
Yes (allergic
subjects)
þþþ þþþ þþþ þ þ þþ þþ BBB þ þ þþþ þ 157,166,
168–172
Respiratory (nasal)
provocation test
Yes (allergic
subjects)
þþþ þþþ þþþ þþþ þþ þþ þ BBB þþ 0 þþþ 0 173,174
Labial/nasal/oral
provocation test
Yes (allergic
subjects)
þþþ þþþ þþþ þ þ þþ þ BBB þþ 0 þþþ 0 82,83,175
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Table 2. Continued
Clinical relevance* Biological sensitivity* Feasibility* Plausibly linked to†
Functions Markers
Mainly
relevant for
specific
subpopulations
Differentially
expressed
Correlates
with
clinical
endpoint
Linked to
causal
pathway
Within-
subject
variation
Between-
subject
variation Technical Robustness
Arbitrary
marker
score‡ Practicality* Pathogens Allergy Inflammation
Example
references
Symptomatic
inflammation
Incidence of symptoms Yes (patients) 0 (þ )§§ 0 (þþ)§§ 0 ( þ þ)§§ þ þ þþ þþ A (BB)§§ þþ þ þ þ 2,32,156
Duration of symptoms Yes (patients) 0 (þ )§§ 0 (þþ)§§ 0 (þþ)§§ þ þ þþ þþ A (BBB)§§ þþ þ þ þ
Severity of symptoms Yes (patients) 0 (þþ)§§ 0 (þþ)§§ 0 (þþ)§§ þ þ þþ þþ A (BBB)§§ þþ þ þ þ
Response to
inflammatory
challengeskk
Kinetics and amplitude
of induced inflam-
matory response
(assessed as acute-
phase protein,
cytokine or gene
expression)
No þ þ þþ þ þ þþ þ A (B){{ þþ þ þ þþþ 31,176–179
NA, not applicable (cannot be assessed repeatedly in the same subject due to the development of immunological memory); DTH, delayed-type hypersensitivity; CHS, contact hypersensitivity; GI, gastrointestinal; ARIA, Allergic Rhi-
nitis and its Impact on Asthma; TRACK, Test for Respiratory and Asthma Control in Kids.
* See Table 1 for score interpretation.
†þþþ , Most relevant; þþ , next most relevant; þ , somewhat relevant; 0, not relevant.
‡ Arbitrary marker score is based on subjective expert judgement on the usefulness of a marker based on weighed evaluation of individual criteria. A, Not very useful; B, low suitability; BB, medium suitability; BBB, high suitability.
§ Response to natural acute infections of respiratory tract (e.g. influenza virus and rhinovirus) or gastrointestinal tract (e.g. Clostridium difficile, enterotoxigenic Escherichia coli (ETEC) and rotavirus) or to natural chronic infection
(e.g. cytomegalovirus (CMV), Epstein–Barr virus or Helicobacter pylori).
kþþ Indicates natural chronic infections (e.g. CMV and Epstein–Barr virus); 0 indicates acute infections.
{Pathogen-specific immune response such as pathogen-specific antibody titre or seroconversion or pathogen-specific T-cell response. Note that as with most natural infections, it is difficult to identify the responsible pathogen.
** Response to experimental infection (e.g. experimental rhinovirus infection, experimental infection with attenuated ETEC or experimental infection with respiratory syncytial virus).
†† Response to injected (systemic) or oral (mucosal) vaccination.
‡‡ Mainly relevant in GI patient populations.
§§ First score for low-grade metabolic inflammation, given in parentheses for patients with inflammatory conditions.
kkResponse to injected endotoxin, oral fat load, oral glucose load and exercise challenge and initial innate (inflammatory) response to vaccination. Still mainly experimental.
{{Responses to inflammatory challenges seem promising, but relevance remains to be largely established.
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Table 3. Ex vivo and basal immune function markers
Clinical relevance* Biological sensitivity* Feasibility* Plausibly linked to†
Functions Markers
Mainly relevant
for specific
subpopulations
Differentially
expressed
Correlates
with
clinical
endpoint
Linked
to
causal
pathway
Within-
subject
variation
Between-
subject
variation Technical Robustness
Arbitrary
marker
score‡ Practicality* Infection Allergy Inflammation Example references
Systemic immune function
markers
Ex vivo (integrated)
Immune risk profile
(specific to elderly
individuals)
Predefined profile (e.g.
CD4:CD8 ratio, B-cell
count, proliferative
response, naive cell
counts, NK-cell activity
and phagocyte function)
Yes§ þþ þþ þ þ þ þ þ BB þ þþþ 0 þþ 180–183
Ex vivo innate
Phagocyte function Phagocytosis No þþ þþ þþ þ þ þ þ BB þ þþþ 0 0 184–193
Oxidative burst No þ þþ þþ þ þ þ þ BB þ þþþ 0 0
Migration of cells No 0 þþ þþ þ þ þ þ BB þ þþþ 0 þ
NK-cell function NK-cell activityk No þþ þþ þþ þ þ þ þ BB þ þþþ 0 0 15,194–202
LAK cell activityk No þþ þþ þþ þ þ þ þ BB þ þþþ 0 0
APC function Expression of activation and
differentiation markers
(e.g. CD83, CD80, CD86,
CD40 and HLA-DR)
No þþ þ þþ þ þ þ þ BB þ þþþ þþ þþ 15, 203–210
Expression of TLR No þþ þ þþ þ þþ 0 þ BB þ þþþ þþ þþ
Bioactive mediator
production (by PBMC
or whole blood)
Production of cytokines
(pro-/anti-inflammatory
profiles)
No þþ þ þþ þ þþ þþ þþ BB þþ þþþ þþ þþþ 127,211–218
Production of eicosanoids No 0 þ þ þ þ þ 0 B þ þþþ þþþ þþþ
Ex vivo adaptive
T-cell functionk Proliferation{ No þþ þþ þþ þ þ þþ þ BB þþ þþþ þþ þþ 219–221
Expression of activation mar-
kers (e.g. CD25, CD69,
CD95 and HLA-DR)
No þþ þþ þþ þ þ þþ þ BB þþ þþþ þþ þþ 127,143,144,203,222–224
Production of cytokines
(e.g. Th1/Th2/Th17)
No þþ þþ þþ þ þ þþ þ BB þþ þþþ þ þþþ 225–230
Cytotoxicity No þþ þþ þþ þ þ þþ þ BB þ þþþ þ þþ 231,232
Treg function No þþ þþ þþ þ þ þ þ BB þþ þþþ þ þþþ 233–238
B-cell functionk Production of Ig (polyclonal
or specific)
No{ þ þ þ þ þ þþ þ B þþ þþ þþ þ 120,239
Ig class switch No 0 þ 0 þ þ þ þ A þþ þþ þ þ 123,127,240,241
Specific IgE
sensitisation
Basophil activation test Yes (allergic) þþþ þþþ þþ þ þ þþ þ BBB þþ 0 þþþ 0 111,112,115,222,242–244
Basal markers (numbers
or concentrations in
blood or plasma)
Cells Differential cell counts No þþ þþ þ þþ þþ þþ þþþ BB þþ þþ þ þþ 181,243,245
Basic lymphocyte subsets
(e.g. T, B, NK and
CD4:CD8 ratio)
No þ þ þ þþ þþ þþ þþ B þþ þþþ þ þþ 28,59,222
Sophisticated subsets (e.g.
CD45RA/RO, Treg, Natural
Killer T-cells (NKT),
pDC and mDC)
No þ þ þ þþ þþ þþ þ B þ þþ þ þþ 28,127,222,246
Expression of activation mar-
kers (e.g. CD25, CD69,
CD95 and HLA-DR)
No þ þ þ þ þþ þþ þþ B þþ þþþ þ þþ 243,247
T- and B-cell repertoires
(clonality)
No** þ þ þ þ þ þ þ A þþ þþþ þþ þþ 123,126,248,249
Mediators Acute-phase proteins (e.g.
CRP and fibrinogen)
No þþ þþ þ þ þ þþþ þþþ BB þþ þþ 0 þþþ 116,250–253
Antigen-specific antibodies No þþ þ þþ þþ þþ þþ þ BB þþ þþ þþ þ 254
Allergen-specific IgE Yes (allergic) þþ þþ þþ þþ þþ þþ þþ BBB†† þþ þ þþþ 0 114,255–261
Ig isotypes (including
total IgE)
No þ þ þ þþ þþ þþþ þþþ B þþ þþ þþ þ 25,262
Complement components No þ þ þ þ þ þþþ þ B þþ þþ þ þ 263,264
R
.
A
lb
e
rs
et
a
l.
S1
2
British Journal of Nutrition
https:/w
w
w
.cam
bridge.org/core/term
s. https://doi.org/10.1017/S0007114513001505
D
ow
nloaded from
 https:/w
w
w
.cam
bridge.org/core. U
niversity of B
asel Library, on 10 Jul 2017 at 15:47:45, subject to the C
am
bridge C
ore term
s of use, available at
Table 3. Continued
Clinical relevance* Biological sensitivity* Feasibility* Plausibly linked to†
Functions Markers
Mainly relevant
for specific
subpopulations
Differentially
expressed
Correlates
with
clinical
endpoint
Linked
to
causal
pathway
Within-
subject
variation
Between-
subject
variation Technical Robustness
Arbitrary
marker
score‡ Practicality* Infection Allergy Inflammation Example references
Cytokines, chemokines and
matrix metalloproteinases
No þ þ þ þ þ þþ þ B þþ þþþ þþ þþþ 183,212,265,266
Profiles of cytokines (e.g.
pro-/anti-inflammatory and
Th1/Th2/Th17)
No þþ þþ þ þ þ þþ þ BB þþ þþþ þþ þþþ 267–269
Soluble receptors (e.g.
sCD14, sVCAM1 and
sICAM1)
No þ þ þ þ þ þþ þ B þþ þ 0 þþþ 204,270,271
Adipokines (e.g. adiponectin,
leptin and IGF)
No þþ þ þ þ þ þþ þ B þ þ 0 þþþ 265,272–277
Serum calprotectin No þ þ þ þ þþ þþ þ A þþ þ 0 þ 278,279
Tryptase Yes (allergic) þþþ þþþ þ þþ þ þþ þþ BBB þþ 0 þþþ þ 113,280–283
Local immune function
markers
Ex vivo markers
Local immune function Functional assays on biopsy
material (e.g. from the
intestine, adipose tissue
and skin)
Yes þþ þþ þþ þ þ 0 þ BB 0 þþ 0 þþþ 284–286
Functional assays on nasal
or bronchoalveolar lavage
Yes þþ þþ þþ þ þ 0 þ BB 0 þþ þþþ 0 287–289
Basal markers (numbers
and/or concentrations
in blood, plasma, saliva
and faeces)
Cells Cellularity of biopsies or
lavage
Yes þþ þþ þþ þ þ 0 þ BB 0 þþ þþ þþþ 287–289
Homing markers on circulat-
ing cells
No þ þ þþ þ þ þþ 0 B þþ þþ þ 0 285,290
Soluble mediators Stool calprotectin No‡‡ þ þþ þ þ þ þ þ BB þ þþþ 0 þþþ 291–293
Secretory and stool Ig
(mucosal IgA)
No þþþ þþþ þþ þþ þ þ þþ BBB þþ þþþ þ þþþ 40,103,104,107,109,
294–296
Cytokine concentration,
e.g. in faecal
water/BAL/sputum
No þ þ þ þ þ þ þ A þ þ þ þþ 297–304
Mucus Amount of degradation of
mucus
Yes þ þ þ þ þ þþ þ A þ þþþ þþ þþþ 13,305–307
CD, cluster of differentiation; NK, natural killer; LAK, lymphokine-activated killer cells; APC, antigen-presenting cells; HLA, human leucocyte antigen; TLR, Toll-like receptor; PBMC, peripheral blood mononuclear cells; Th, T helper;
Treg, regulatory T cell; pDC, plasmacytoid dendritic cells; mDC, myeloid dendritic cell; CRP, C-reactive protein; sVCAM, soluble vascular cell adhesion molecule; sICAM, soluble intracellular adhesion molecule; IGF, insulin-like
growth factor; BAL, bronchoalveolar lavage.
* See Table 1 for score interpretation.
†þþþ , Most relevant; þþ , next most relevant; þ , somewhat relevant; 0, not relevant.
‡ Arbitrary marker score is based on subjective expert judgement on the usefulness of a marker based on weighed evaluation of individual criteria. A, Not very useful; B, low suitability; BB, medium suitability; BBB, high suitability.
§ Is associated with all-cause mortality in elderly individuals; relevance in other (sub)populations to be established.
kPractical feasibility: 0 for Cr, þþ for flow cytometry.
{Assessed after polyclonal, oligoclonal or antigen-specific stimulation.
** Less clarity on relevance and much more variability in infants.
†† Specific IgE (sIgE) clearly indicates the involvement of immune function, but its relevance is controversial in the absence of concurrent clinical assessment. Some see it as a clinically relevant marker also used to guide therapy,
whereas others (including the European Food Safety Authority) emphasise that not all allergic subjects have sIgE, not all subjects with sIgE have allergic symptoms and changes in sIgE are not always associated with changes
in symptoms.
‡‡ Mainly relevant in gastrointestinal patients.
Im
m
u
n
e
m
o
d
u
latio
n
b
y
n
u
tritio
n
S1
3
British Journal of Nutrition
https:/w
w
w
.cam
bridge.org/core/term
s. https://doi.org/10.1017/S0007114513001505
D
ow
nloaded from
 https:/w
w
w
.cam
bridge.org/core. U
niversity of B
asel Library, on 10 Jul 2017 at 15:47:45, subject to the C
am
bridge C
ore term
s of use, available at
certain fold increase in specific antibody titres before and
after vaccination(86), e.g. at least a fourfold rise in the case
of influenza vaccines(88).
Delayed-type hypersensitivity (DTH) and contact hyper-
sensitivity responses are local cell-mediated inflammatory
responses triggered in sensitised individuals by the cutaneous
administration of an antigen. Such responses can be measured
24–48 h after antigen application as epidermal induration(89).
For diagnostic purposes, DTH responses such as the prototy-
pic Mantoux test have been largely replaced by more specific
methods; however, as indicators of integrated in vivo cellular
immune responsiveness, they remain valuable markers of
immune function. However, standardised application has
become complicated since the Cell Mediated Immunity
(CMI) Multitest, in which seven different common antigenic
preparations are administered simultaneously, is no longer
available. Rigorously standardised application of antigenic
material by syringe or prick is occasionally used; however,
since application only yields DTH responses in sensitised
subjects, it is important to apply a range of antigens. These
problems have been overcome in several studies by experi-
mentally sensitising subjects to uncommon chemical antigens
not normally encountered. In this way, all subjects will
respond, and the effect of nutrition on both the sensitisation
and the elicitation phase of contact hypersensitivity responses
can be assessed(90,91). Although this is scientifically very attrac-
tive, there are clear ethical constraints. The same holds true
for the assessment of Langerhans cells in skin biopsies,
which can be used to assess temporal depletion of Langerhans
cells due to migration induced by UV radiation. This is asso-
ciated with increased susceptibility to (skin) infections, and
mitigation of this depletion can, therefore, serve as a relevant
marker of skin immune function(92).
The physical barrier of the gastrointestinal tract is central to
the protection of the body against infections, allergens and
inflammatory stimuli alike(93–96). Tests designed to examine
the integrity of the intestinal barrier typically involve the
appearance of marker substances in plasma or urine after
oral application of such substances (most often a non-
metabolised sugar) and/or of resident bacteria or components
thereof such as endotoxins after translocation from the lumen
of the intestine into the circulation. These markers are con-
sidered useful to assess alterations in intestinal barrier func-
tion, which is considered important in gastrointestinal
infections and (food) allergies as well as low-grade inflam-
mation. However, in the strict sense, such markers do not
necessarily demonstrate alterations in (mucosal) immune function
as the permeability may be altered by non-immunological
mechanisms.
In vivo provocation tests with allergens aim to reproduce
allergic reactions in conditions as close as the natural exposure
and using a lower dose and standardised conditions of
exposure. Allergen provocation tests include intradermal
injection or trans-cutaneous patches on the skin(97,98), oral
provocation with food allergens(99,100) and mucosal (nasal,
conjunctival, bronchial or labial) provocation with aller-
gens(101,102). While allergen provocation tests are quite safe
to be used for most people, the possibility of anaphylaxis
does exist and such tests should, therefore, only be done
under clinical supervision.
Responsiveness to experimental inflammatory challenges has
been suggested as a useful marker of inflammatory resilience.
This involves the assessment of transient inflammatory
responses induced by metabolic stressors (e.g. oral glucose or
lipid load), infection stressors (e.g. injection with lipopolysac-
charide, TNF, or IL-6 or the early response to the adjuvant com-
ponents of vaccines) or tissue damage (e.g. acute exercise
and exposure to UV radiation). Such dynamic responses to
inflammatory challenges are promising markers of inflamma-
tory resilience and are likely to be more relevant indicators of
the ability to maintain inflammatory homeostasis than the
mere static assessment of acute-phase proteins (e.g. CRP) or
cytokines. However, there is a clear need for further standardis-
ation of experimental protocols, and relevance in the general
population remains to be established in prospective studies(31).
The evaluation of a range of ex vivo and basal markers of
immune function is summarised in Table 3. It is beyond
the scope of this article to provide detailed technical
information on the assessment of all of these immune function
markers as they are quite commonly used and specific
considerations have been discussed in a detailed manner
elsewhere(1,18,22–25,27). The references listed in the table
provide pointers to specific details on the use of individual
markers in nutrition studies.
Clustering of markers according to clinical relevance and
involvement of immune functions
A selection of the most relevant markers given in Tables 2
and 3 are further categorised in Table 4 according to
the most relevant functional domain (horizontally) while
indicating (vertically) whether the markers by themselves are
classified into the following groups. Group A is indicative of
clinical relevance and involvement of immune function(s)
(e.g. response to vaccination). Group B is indicative of clinical
relevance but not necessarily of the involvement of
immune function(s) (e.g. symptoms of diarrhoea). Group C
is indicative of the involvement of immune function(s)
and is associated with clinical relevance in specific (sub)
populations (selected markers such as NK-cell activity,
which is associated with infection risk in athletes and elderly
individuals). Group D provides mechanistic insight into details
of the immune function(s) involved, but not necessarily of
clinical relevance (e.g. circulating levels of cytokines).
This classification helps in the interpretation of study out-
comes and can also be used to further rationalise the selection
of markers for inclusion in future studies. To some extent, it
may also guide in making decisions in preclinical investigations.
Clearly, markers of group A are most useful as they provide evi-
dence for both clinical relevance and involvement of immune
function(s) by themselves. However, it may not always be feas-
ible to select markers from this group. In such cases, combining
the assessment of markers from group B with that of markers
from group C or D will lead to more confidence in the future
interpretation of the data regarding clinical relevance and invol-
vement of altered immune function(s). The same argument
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applies for a combination of group A markers with group C or D
markers, linking clinical relevance with mechanistic insight.
Such approaches will also result in new datasets that may be
used to establish correlations of particular group C or D markers
with clinical endpoints, which may lead to their evolution into
group A markers within a reasonable time frame. In contrast,
measuring numerous group B markers alone will lead to results
that may be very clear regarding the clinical relevance, but
remain inconclusive on the involvement of (altered) immune
functions. Likewise, studies that focus exclusively on group D
markers may very convincingly demonstrate that particular
immune functions are altered, but the clinical relevance of
these changes will remain largely elusive.
The list of markers given in Table 4 is non-exhaustive and
should not be regarded as final since markers may evolve
if more data become available. Instead, Table 4 provides
the next step in a rational approach towards the design and
interpretation of studies that aim to establish effects on
immune function in the general population. The markers men-
tioned serve to illustrate how changes in these markers due to
exogenous factors such as nutrition could be interpreted in the
context of different scenarios described below. Selection and
classification of the markers are based on the authors’ expert
judgement aided by discussion of an earlier version of this
table with a wider group of experts.
It is noteworthy that many of the valuable group A markers
indicating both clinical relevance and involvement of the
immune system are ‘challenge tests’ comprising the assess-
ment of in vivo responses of the immune system to a relevant
(experimental) challenge. For defence against pathogens,
these include immune responses to an (experimental) infec-
tion, to a vaccination and to a challenge with a recall antigen
using a DTH or contact hypersensitivity test. For avoidance or
mitigation of allergy, commonly used allergen provocation
tests such as prick, intradermal and patch tests and labial, res-
piratory and oral challenges with specific allergens fall into
this category. The corresponding pro-inflammatory challenge
tests hold great promise as markers of the resilience of
inflammatory control, but their clinical relevance has not
been established yet(31). For the time being, pro-inflammatory
challenge tests are, therefore, classified as group C markers.
In addition to the challenge tests, several other markers
are placed in group A because they are clear indicators of
the involvement of the immune system and their clinical rel-
evance in the general population has been established, and
modulation in the relevant direction would, therefore, be con-
sidered a beneficial health effect. For instance, mucosal IgA is
a group A marker for defence against pathogens because it
is a marker of immune function and low (salivary) IgA
is a risk factor for respiratory infections in children and
athletes(103–110). For avoidance or mitigation of allergy, the
basophil activation test(111,112) and tryptase(113) in plasma are
considered group A markers because they reflect basophil
reactivity in allergic patients and are considered risk factors
correlated with the severity of the reaction. Allergen-specific
IgE (sIgE) clearly indicates the involvement of immune
function; however, in the absence of concurrent clinical assess-
ment, its relevance in the general population is controversial.
Some consider it as a clinically relevant marker (risk factor),
whereas others (including the European Food Safety Auth-
ority) emphasise that not all allergic subjects have sIgE, not
all subjects with sIgE have allergic symptoms and changes in
sIgE are not always associated with changes in symp-
toms(114,115). To acknowledge this controversy, we have indi-
cated sIgE in groups A and C.
Group B markers are clinically relevant markers or end-
points (symptoms) that indicate the relevance of an effect,
but in isolation do not prove the involvement of altered
immune function as the effects could also be mediated via
other mechanisms. For defence against pathogens, these
include pathogen load and symptoms of common respiratory
tract or gastrointestinal infections. Likewise, for avoidance or
mitigation of allergy, symptoms of allergic responses due to
undefined natural exposure to allergens indicate clinical rel-
evance, but lack the specificity to prove the involvement of
the immune system. This is also true for in vivo challenges
with whole food products (milk) or substances such as lactose
to which subjects may also respond with non-immune system-
mediated intolerance. Low-grade inflammation does not lead
to overt symptoms in the general population but is associated
with reduced sensitivity to insulin and increased systolic blood
pressure. However, these symptoms are not specific to low-
grade inflammation and can also be modified by other non-
immune system-mediated processes.
Group C markers typically reflect critical immune functions
involved in the pathophysiological pathways underlying
clinically relevant symptoms. Unlike group A markers, these
markers are not generally accepted as markers of clinical
relevance by themselves (risk factors), but there is ample evi-
dence from relevant subpopulations that (alterations in) these
markers are associated with (alterations in) clinical outcomes,
and this is supported by a plausible mechanism of action. For
instance, the precise predictive value of ex vivo NK-cell,
phagocyte, or (pathogen-specific) T- or B-cell functions for
infection risk is unknown. However, these immune functions
are plausibly involved in the defence against pathogens, and
a range of studies in elderly individuals, athletes, shift workers
and other subpopulations have demonstrated that these ex
vivo functional markers are inversely associated with the
occurrence of symptomatic infections. Likewise, depletion of
Langerhans cells in the skin due to UV radiation has been
shown to be associated with an increased risk of (skin)
infections, which plausibly is related to the reduced ability
to present antigens and thus mount a protective immune
response. For avoidance or mitigation of allergy, some feel
that sIgE falls into this category for reasons discussed above.
In addition, the remainder of ex vivo allergen-specific Th1-
and Th2-cell function, Treg function and antigen-presenting
cell function fall into this category. For the time being, in
vivo responses to a pro-inflammatory challenge are a group
C marker for inflammation control, but they may evolve to a
group A marker if relevance can be established in prospective
cohorts in the general population. Serum markers of the
acute-phase response (such as CRP) or (ratios of) pro- and
anti-inflammatory mediators do define low-grade asympto-
matic inflammation, but are not accepted as proof of clinical
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Table 4. Clustering of selected markers according to clinical relevance and involvement of immune function(s)
Markers of immune function linked to
Classification Defence against pathogens
Avoidance or mitigation of hypersensitivity
(e.g. allergy)
Inflammation control (reduction
of low-grade metabolic
inflammation)
Group A
marker
Indicative of clinical relevance and involve-
ment of immune function(s)
Pathogen-specific immune response (specific
antibodies and specific T-cell response
after natural or experimental infection)
Specific response or symptoms after an
experimental allergen challenge (skin,
labial, respiratory or oral provocation tests)
NA
Vaccine-specific immune response (seropro-
tection, seroconversion, specific antibodies
and specific T cells)
Basophil activation test
Specific DTH or CHS response Tryptase in plasma
Mucosal IgA (in saliva, tears, etc.) Allergen-specific IgE (sIgE)*
Group B
marker
Indicative of clinical relevance but not
necessarily of the involvement of immune
function(s) (i.e. clinical symptom)
Symptoms of infection (incidence, duration
and severity after natural or experimental
infection)
Symptoms of allergy (rhinitis, asthma, urti-
caria, eczema, GI manifestations, etc.)
Symptoms associated with low-
grade inflammation (e.g. insulin
resistance and blood pressure)
Pathogen load Response to general food provocation
Group C
marker
Indicative of the involvement of immune
function(s) and associated with clinical
relevance in specific (sub)populations
Ex vivo (pathogen-specific) B-cell function Allergen-specific IgE (sIgE)* In vivo response to a pro-inflamma-
tory challenge
Ex vivo (pathogen-specific) T-cell function Ex vivo (allergen-specific) Th1/Th2-cell
function
Markers of acute-phase response
(CRP, TNF, IL-1, IL-6 and blood
sedimentation)
Ex vivo phagocyte function Ex vivo (allergen-induced) production of
Th1/Th2 mediators
(Ratio of) pro- and anti-inflamma-
tory mediators
Ex vivo NK-cell function Ex vivo Treg-cell function Ex vivo Th1/Th17/Treg-cell function
Migration of Langerhans cells Ex vivo APC function Ex vivo oxidative burst
Group D
marker
Provides mechanistic insights but not
necessarily into clinical relevance
(non-exhaustive list of examples)
Markers of acute-phase response (CRP,
TNF, IL-1, IL-6 and blood sedimentation)
Markers of acute-phase response (CRP,
TNF, IL-1, IL-6 and blood sedimentation)
Plasma adiponectin and leptin
(Ratio of) pro- and anti-inflammatory
mediators
(Ratio of) pro- and anti-inflammatory
mediators
Plasma endotoxin (LPS)
Percentage of subsets including CD4:CD8
ratio
Total IgE Plasma and faecal calprotectin
Circulating or ex vivo-produced antibodies
(not antigen- or vaccine-specific)
Circulating cytokines
Circulating or ex vivo-produced cytokines Plasma and faecal calprotectin
NA, not applicable; DTH, delayed-type hypersensitivity; CHS, contact hypersensitivity; sIgE, specific IgE; GI, gastrointestinal; Th, T helper; CRP, C-reactive protein; NK, natural killer; Treg, regulatory T cell; APC, antigen-presenting
cells; LPS, lipopolysaccharide.
* sIgE clearly indicates the involvement of immune function, but in the absence of concurrent clinical assessment, its relevance is controversial. Some see it as a clinically relevant marker also used to guide therapy, whereas others
(including the European Food Safety Authority) emphasise that not all allergic subjects have sIgE, not all subjects with sIgE have allergic symptoms and changes in sIgE are not always associated with changes in symptoms.
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relevance in the general population. Nonetheless, there is a
wealth of emerging data in various subpopulations including
elderly individuals and obese and insulin-insensitive subjects,
demonstrating that (alterations in) levels of these markers
are associated with an increased risk of cardiovascular
events and diabetes(116–119). To a lesser extent, the same
holds true for ex vivo oxidative burst and functionality of
Th1, Th17 and Treg subsets, all of which are, therefore, also
considered group C markers.
Group D markers also indicate the involvement of particular
immune functions, but contrary to group C markers, their
critical involvement in the pathophysiology is less established
and there is no convincing evidence (yet) that changes in
these markers are associated with changes in relevant clinical
outcomes. This has implications for the ability to interpret
changes observed in these markers, as will be discussed
below. In essence, group D contains ‘all other’ markers of
immune function. The examples mentioned in Table 4 serve
to contrast the categorisation of the same marker for different
functional domains, such as markers of acute-phase response
and (ratio of) pro- and anti-inflammatory markers as group C
markers for inflammation control v. group D markers for
defence against infection and avoidance or mitigation of
allergy. Other examples contrast different markers within
one functional domain, such as sIgE (group A or C) v. total
IgE (group D) for avoidance of allergy or plasma adiponectin
and leptin (group D) v. (ratio of) pro- and anti-inflammatory
mediators (group C) for inflammation control.
It is important to note that for control of low-grade asymp-
tomatic inflammation, there are no specific markers indicating
clinical relevance (group A or B). Insulin resistance and blood
pressure are very unspecific, and the clinical relevance of the
most useful markers in this domain including response to
inflammatory challenge, CRP and inflammatory mediators
remains to be established in the general population. This
lack of markers to establish clinical relevance severely
hampers proper interpretation of effects on markers of
low-grade inflammation. It is, therefore, of critical importance
for progress in this area to establish the clinical relevance of
the most promising markers using prospective cohorts in the
general population. Such efforts should not only focus on
concentrations or ratios of circulating inflammatory mediators,
but also include responsiveness to rigorously standardised
in vivo pro-inflammatory challenge tests as these types of
challenge tests have been shown to be most useful in the
other domains of immune function.
Scenarios to interpret changes in (sets of) markers
Following the definition of criteria, prioritisation of markers
and classification according to conclusiveness for clinical rel-
evance and involvement of immune function, we set out to
devise a framework for the interpretation of changes observed
in the different types of immune function markers, taking into
account the type of marker and the changes observed relative
to a defined reference range. Obviously, the proposed
approach does not discount the need to critically consider
the quality of individual studies and consistency of effects
and to base the ultimate conclusions on the totality of evi-
dence. Herein, we propose a theoretical framework to struc-
ture the interpretation of changes in immune function
markers due to nutrition in the general population. As
depicted and explained in more detail in Fig. 3, five scenarios
were defined for changes in markers relative to the appropri-
ate reference range.
The first step to interpret immune modulation in a particular
setting is to determine whether one or more relevant markers
of immune function are statistically significantly modulated by
the intervention and, if so, to determine which of the scenarios
applies. If the marker by itself indicates clinical relevance but
not altered immune function (group B), and the effect is not
accompanied by a plausibly linked change in a marker indi-
cating altered immune function, then the effect is clinically rel-
evant but may not necessarily be due to altered immune
function and cannot be interpreted as such (e.g. reduced inci-
dence or severity of diarrhoea on its own). If the marker by
itself is indicative of immune function(s) and clinical relevance
(group A marker), then the result can be interpreted as a ben-
eficial modulation of immune function for scenarios 1, 2, 4
and 5. In scenario 3, this raises some concern and needs to
be evaluated in more detail as described below. If the
marker by itself is indicative of immune function(s), but in iso-
lation does not indicate clinical relevance (group C), then
interpretation as a beneficial modulation of immune function
is possible for scenarios 1, 2, 4 and 5, if in the same or a similar
study setting (a similar population or the same nutritional
intervention), a marker indicating clinical relevance (group A
or B) is also significantly changed and the changes are
linked via a plausible mechanism. Again, for scenario 3,
further evaluation is required to assess the potential for
detrimental modulation of immune function, especially after
prolonged exposure. For scenario 4, interpretation as a ben-
eficial immune modulation would also be possible, but in
this case, the intervention would prevent the negative changes
occurring in the reference or control group. Finally, if the
change is observed in a marker indicating altered immune
function(s) but not necessarily clinical relevance in all popu-
lations (group C) and information on the markers of clinical
relevance is lacking in the same or a similar study, then
interpretation of the immune effects is not possible in scenario
1, but may indicate a beneficial modulation in specific cases
(scenarios 2, 4 and 5). This is depicted in Fig. 4. To explore
this approach in more detail, it is applied to five scenarios
discussed below with some examples for the different func-
tional domains.
Scenario 1: nutrition induces a significant modulation
of a marker within the reference range
If a relevant marker of immune function is statistically signifi-
cantly modulated in the relevant direction and the marker
per se is also indicative of the clinical relevance of effects
observed (group A marker), such as improved responsiveness
to an infection or a vaccine or reduced responsiveness to an
(oral) allergen provocation test, then the modulation of this
response within the reference range would be interpreted as a
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beneficial modulation of immune function within the specific
domain. It is critical to consider the changes in immune func-
tions within the context of a specific functional domain as for
some markers the interpretation may differ depending on the
domain. For instance, in the context of defence against patho-
gens, enhanced DTH to an antigenic challenge would be
regarded as an enhanced response to a ‘model infection’ and
would thus be considered beneficial. However, in the context
of allergy, enhancement of a (delayed-type) hypersensitive
response to an allergen challenge would be undesirable,
whereas mitigation of such a response would be considered
beneficial.
Similarly, if a statistically significant change in a marker
indicative of immune function (group C) is plausibly linked
to a statistically significant change in a marker of clinical
relevance (group B marker), then the modulation of this
marker could be interpreted as beneficial, and one can claim
that nutrition improves immune defence against pathogens
or helps to avoid or mitigate allergy or inflammation. For
example, if consumption of a certain nutrient significantly
reduced the duration of gastrointestinal infections during the
winter season (group B) compared with a control group
and concomitantly phagocyte function (group C) increased
within the reference range in the infected subjects and these
are plausibly linked based on mechanistic insights, the
interpretation would be that this nutrient improves immune
defence against pathogens. Another example in the field of
allergy would be if consumption of a certain nutrient signifi-
cantly reduced the severity of rhinitis (group B) compared
with a control group and concomitantly Th2-cell function
(group C) decreased within the reference range for the general
population. In such cases, the interpretation would be that this
nutrient mitigates hypersensitivity against allergens because
these two markers are plausibly linked.
If the immune function marker belongs to the category of
markers that are only indicative of the involvement of the
immune system (group C or D) and evidence for concomitant
changes in the markers of clinical relevance in the same or
similar studies is lacking, then modulation within the reference
range cannot be interpreted in terms of its health impact.
However, complemented with other studies with acceptable
biomarkers, such data could be used as supportive evidence
of an immune regulatory effect. Finally, if the marker is indica-
tive of clinical relevance but there is no significant change in
plausibly associated markers of immune function (group B
alone), clearly this is beneficial to health, but the effect may
not necessarily be due to altered immune function and
should not be interpreted as such. For instance, if the inci-
dence or duration of diarrhoea is significantly reduced, this
is beneficial. However, without additional information on
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Fig. 3. Graphical representation of the five different scenarios for the modulation of immune function markers relative to the reference range. Scenario 1: statisti-
cally significant modulation within the reference range or within the range of a relevant control population, a very common scenario for modulation due to nutrition.
Scenario 2: statistically significant modulation from outside the reference or control range of a relevant control population back into the range. Cases are different
before intervention and become similar after intervention. Scenario 3: statistically significant modulation from within the reference or control range of a relevant
control population out of the range. Cases are similar before intervention and become different after intervention. Scenario 4: nutritional prevention of statistically
significant modulation induced by other endogenous or exogenous factors. Markers move out of the reference range of a relevant control population in the refer-
ence group, but this is prevented by nutrition in the intervention group (e.g. prevention of negative effects on the immune function of ageing or UV-B exposure or
prevention of allergic sensitisation). Scenario 5: statistically significant modulation from a less favourable reference range to the reference range of a comparator
group with a more desired immune function (e.g. from bottle-fed infants to breast-fed infants, elderly individuals to healthy adults, strenuous exercise to healthy
controls, sleep deprivation to sleep sufficiency, etc.).
R. Albers et al.S18
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114513001505
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:47:45, subject to the Cambridge Core terms of use, available at
changes in plausibly linked markers of immune function, this
cannot be interpreted as a beneficial modulation of immune
function because the underlying mechanism may be comple-
tely different.
Scenario 2: nutrition induces a significant modulation of a
marker from outside the reference or control range back
into the range
The interpretation for this scenario is essentially identical to
that for scenario 1 with one addition. In the absence of data
on changes in clinical relevance in the same or a similar
study (the same intervention in a similar population), changes
in markers indicative of immune function (group C) could
potentially also be interpreted using a two-step argumentation
if a change in these markers is described in the literature to be
strongly associated with health improvement. An example
may be if a (nutritional) intervention induced an increase in
NK-cell activity back to the reference range and it is known
that decreased levels of NK-cell activity have been strongly
linked in the literature with decreased defence against patho-
gens or tumours in particular populations (e.g. athletes and
elderly individuals). If there is no such established association
with clinically relevant outcomes in the literature, then the
interpretation of the relevance of immune function marker
modulation back to the reference range is not possible
(group D). However, one could argue that modulation back
into the reference range could be positively perceived in
terms of reassurance against potential negative effects.
Scenario 3: nutrition induces a significant modulation
of a marker from within the reference or control range
to outside the range
If particular markers of immune function move from within
the reference range to outside the reference range, such
results should be interpreted within their context. In such situ-
ations, it may be useful to take the timing and sequence of
events into account. For instance, if this occurs during an
acute infection process, allergic manifestation or inflammatory
episode, then the out-of-range markers may be more
attributable to the ongoing host response to the infection/
Significant modulation of marker(s)?
Significant modulation of marker(s)
indicative of immune function?
Yes No
Yes
Group A/C/D marker
Is the marker by itself indicative of
biological/clinical relevance?
Group B marker
Group A marker
Scenarios 1, 2, 4 and 5
Beneficial modulation of
immune function
Scenario 3
Potentially undesired
modulation of immune function
Significant modulation of other marker(s)
indicative of biologica/clincal relevance?
(in the same or a similar study)
Group C/D marker
No
No effect
Yes No
Yes
Group C/D+gorup B marker 
Scenarios 1, 2, 4 and 5
Beneficial modulation of
immune function
Scenario 3
Potentially undesired modulation
of immune function
Scenario 1
Interpretation NOT possible
Scenarios  2, 4 and 5
Beneficial modulation of
immune function
Scenario  3
Potentially undesired modulation
of immune function
Scenarios  1–5
Interpretation NOT possible
Group C/D marker 
Group D marker Group C marker 
Is the marker known to be associated with
health improvement in (sub)population?
Health effect, but NOT necessarily
due to immune modulation
No
Yes No
Fig. 4. Flow chart to aid the interpretation of changes in immune function markers in nutrition studies based on information on the type of markers in which signifi-
cant changes are observed (groups A–D) and the relative change compared with the reference range (scenarios 1–5). Blue indicates a health effect but not
necessarily due to immune modulation, green indicates beneficial modulation of immune function, orange indicates potentially undesired modulation of immune
function and red indicates no effect or interpretation not possible. Group A, relevance AND the involvement of immune functions (e.g. response to vaccination).
Group B, relevance BUT NOT necessarily the involvement of immune functions (e.g. diarrhoea). Group C, involvement of immune function(s) AND associated
with clinical relevance in specific (sub)populations (e.g. NK-cell activity in athletes and elderly). Group D, mechanistic insights BUT NOT directly associated with
clinical relevance (e.g. cytokines).
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allergens/inflammation rather than to the nutritional interven-
tion. In such cases, it is also important to look at the magni-
tude of the effect and the consistency of changes observed
among related markers. If it is not just a (statistical) artifact,
but a consistent pattern of substantial modulation of related
markers out of the reference range attributable to the interven-
tion, then this is a sign to look more closely at potential
unwanted side effects that could develop if this is sustained
in the longer term.
Normally, such potentially deleterious effects should surface
during animal studies in the preclinical phase. In the event
that these emerge at a later stage, it would be recommended
to initiate (additional) animal studies to gain a better
mechanistic understanding and/or restrict use in humans to
populations that are not at risk for the tentative adverse effects
while initiating a ‘pharmacovigilance’-type study (postmarket-
ing surveillance study). Clearly, a careful consideration of
the risks v. the benefits of longer-term exposure to such
ingredients/products is warranted.
Scenario 4: nutrition prevents a significant modulation
of a marker from within the reference or control range
to outside the range
If particular markers of immune function in the control or
reference group move from within the reference range to out-
side the range due to other factors and this is prevented by
nutrition, this could be interpreted as a beneficial mainten-
ance of normal immune function. In essence, this is the
reverse of scenario 3 and would constitute increased resili-
ence of the homeostatic regulatory mechanisms. This could
involve the prevention of the negative impact of UV-B
exposure or of strenuous exercise on immune function(s) or
prevention or delay of ageing-associated immune senescence.
Likewise, although allergen-sIgE is normally absent in a popu-
lation, if followed prospectively, the levels of allergen-sIgE
will increase in a subpopulation due to allergic sensitisation.
Prevention of such negative effects could be interpreted as a
beneficial modulation of immune function if the marker itself
signifies clinical relevance as well as immune function (group
A) or if evidenceof plausibly linkedmarkers of clinical relevance
(group B) and contributing immune function (group C) can be
combined. In the absence of data on clinical relevance in the
sameor similar studies, preventionof changes inmarkers indica-
tive of immune function (group C) could potentially also be
interpreted using a two-step argumentation if a change in
these markers is described in the literature to be strongly associ-
ated with negative health effects. If there is no established
association with clinically relevant outcomes, then the interpret-
ation of the prevention of modulation of an immune function
marker (group D) out of the reference range is less easy,
although it could be positively perceived as an indication
of increased resilience of homeostatic control. Finally, if the
prevented modulation out of the reference range indicates
clinical significance without evidence for the involvement of
the immune system (group B by itself), the effect is
beneficial for health, but may not necessarily be due to altered
immune function.
Scenario 5: nutrition induces a significant modulation of
a marker from a less favourable reference range into the
reference range of a comparator group with a more
favourable immune function
In this scenario, changes in markers are compared with the
reference range of a population with a more favourable
health profile. This reference range has been linked through
a plausible mechanism to one or more immune functions.
Typical examples would be to restore markers in elderly indi-
viduals to levels in healthy adults, in (overtrained) athletes
back to normal ranges, and in more disease-prone shift
workers to levels in less disease-prone controls with an undis-
turbed biorhythm; to move markers from atopic to normal
ranges; or to shift markers of bottle-fed infants to normal
ranges for breast-fed infants. Again, changes in markers
indicative of clinical relevance or clearly established associ-
ation with a plausible underlying mechanism are key to
interpretation. In the case of immune function markers that
also indicate clinical relevance (group A) or concomitant
changes in plausibly linked group B and C markers, the
interpretation is straightforward. For instance, if the respon-
siveness to vaccination in an elderly population shows
increases to the range typically found for younger adults,
this will be considered as beneficial. Likewise, reduction of
elevated CRP levels in elderly individuals to ranges observed
in healthy adults would be considered beneficial because
lower levels of CRP have been associated with better survival.
Beyond individual immune function markers
In most nutrition intervention studies, (large) sets of immune
function markers are assessed and the interpretation of inter-
vention effects will depend on the consistency of the changes
observed. If related immune function markers show consistent
changes, the interpretation will be easy and will follow
the same logic as for individual markers. For instance, if com-
posite markers such as ratios of pro- and anti-inflammatory
cytokines, ratios of distinct T-helper cell subset-related
activation markers or cytokines, or a specified immune (risk)
profile can be defined before the study, then reference ranges
can be determined for these composite markers and nutrition-
related changes relative to these ranges can help guide the
interpretation as described for individual markers above.
If changes in related markers are not consistent, interpret-
ation is greatly helped by good clinical practices that include
the a priori definition of the most important ‘lead markers’
(typically groups A and B). The interpretation would be
based on changes in these lead markers combined with
mechanistic insights that may help to interpret the differential
effects observed on the other markers. This could lead to the
formulation of a new hypothesis that could then be tested in a
new study specifically designed to test this hypothesis. Pat-
terns or composite markers that are less well defined before
the study, including those emerging from the untargeted use
of high-content multiplexed or -omics approaches, are more
difficult to interpret within this conceptual framework.
However, such approaches could lead to the identification
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of pathways involved and can help to formulate specific
hypotheses that can then be tested in more targeted follow-
up studies.
It is thus advisable to define a priori a cluster of the most
important markers that are predictive of clinical effects or
can be used as supportive evidence of clinical outcomes and
that will aid in the eventual interpretation of the outcome of
the intervention. These may be complemented with secondary
parameters that present a profile that is indicative of a certain
endpoint that may help in the interpretation of the mechan-
isms underlying potential changes in primary outcomes.
The same principles as described above for nutritional inter-
vention studies may apply to other types of interventions and,
with some caution, to observational studies exploring the
relevance of (nutritional) differences between groups.
Conclusions and recommendations
The overall aim of this article is to provide further guidance for
the assessment and interpretation of immune modulation by
nutrition in the general population. To this end, criteria were
defined to evaluate the strengths and weaknesses of symp-
toms and markers to measure changes in immune function.
The markers were evaluated for three distinct domains of
immune function: defence against pathogens; avoidance or
mitigation of allergy; control of (low-grade) metabolic inflam-
mation. Graded criteria were applied to over seventy-five
immune function markers that were rated based on the differ-
ent scores for their overall usefulness (Tables 2 and 3). Not
surprisingly, it was found that markers that involve the stan-
dardised assessment of relevant symptoms (e.g. symptoms of
common infections or allergies) or in vivo responses to a
defined challenge with antigens or allergens (e.g. response
to vaccination or allergen provocation) provide the most
useful indication to interpret the modulation of immune func-
tion. Other useful markers include selected ex vivo markers of
particular immune functions (e.g. NK-cell activity, phagocyto-
sis and responsiveness of specific T-cell subpopulations) and
selected basal markers essential in the exertion of critical
immune functions, such as mucosal IgA for infection resist-
ance, allergen-sIgE and tryptase for avoidance or mitigation
of allergy, and CRP and inflammatory mediators to indicate
low-grade inflammation.
A selection of the most useful markers were further classi-
fied depending on whether a change in the markers by itself
conclusively indicates clinical relevance and/or involvement
of altered immune function. Group A markers indicating
both clinical relevance and involvement of immune function
include pathogen- and vaccine-specific immune responses,
DTH and contact hypersensitivity responses and mucosal
IgA responses for defence against pathogens and for avoid-
ance or mitigation of allergy-specific responses to allergen
provocation, basophil activation and plasma tryptase. No
group A markers were identified for control of low-grade
metabolic inflammation. The classification of allergen-sIgE
was controversial as some regard it to be a group A marker
for allergy, whereas others are less convinced of its clinical rel-
evance in the absence of symptoms in the general population.
Group B markers demonstrating clinical relevance, but not
necessarily the involvement of immune function(s), include
symptoms of infections and pathogen load for defence against
pathogens as well as symptoms of allergy and response to
general food or lactose provocation for allergy and insulin
resistance and blood pressure as rather unspecific symptoms
associated with low-grade metabolic inflammation. Several
ex vivo cellular function assays associated with clinically rel-
evant effects in (sub)groups of the general population and
indicating the involvement of immune function(s) were clus-
tered as group C. In addition, CRP and inflammatory markers
were put into this category for their role in the control of low-
grade inflammation, and some argue that sIgE should also fit
into this category for avoidance or mitigation of allergy. This
group also comprises in vivo responses to pro-inflammatory
challenges, which are considered promising markers for con-
trol of low-grade metabolic inflammation, but direct evidence
for their clinical relevance remains to be established. Further
optimisation, validation and inclusion of such challenge tests
in prospective studies should be a high priority, as there are
currently no other markers specifically indicating clinical
relevance for the modulation of low-grade metabolic
inflammation, hampering possibilities to design studies to
demonstrate benefits of improved inflammatory control.
Finally, group D contains all other immune function markers
that can help to provide mechanistic insights, but for which
the clinical relevance is currently unclear.
Clearly, there is no gold standard of immune function that
can be recommended for all studies assessing the effects of
nutrition on immune function in the general population. It
is, therefore, proposed to first define the functional domain
of interest and then select (combinations of) markers that indi-
cate clinical relevance and for which a plausible hypothesis
explaining how they could be related is available. For
instance, to test the effect on resistance to pathogens, one
could assess the response to a vaccination or combine the
assessment of endpoints with specific responsiveness to an
experimental infection. Alternatively, symptoms of natural
infections could be assessed alongside with markers of
immune function likely to be involved mechanistically. If the
aim of the study is to test effects on mitigation of allergy,
one could focus on provocation tests using specific allergens
or combine the assessment of allergic symptoms with
contributing group C or D markers. Finally, for control of
low-grade metabolic inflammation, one could select a combi-
nation of markers including responsiveness to inflammatory
challenge, CRP and pro- and anti-inflammatory mediators.
However, it is important to realise that the clinical relevance
of these markers remains to be established in the general
population.
To aid the interpretation of changes observed in (combi-
nations of) immune function markers, a framework was
devised taking into account the type of marker and the
changes observed relative to a defined reference range.
Within this framework, five different scenarios were identified
including (significant) modulation within the reference range
(a very common scenario for modulation due to nutrition),
modulation from outside the reference range back into the
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range, modulation from within the reference range out of the
range, prevention of modulation induced by other factors, and
modulation into the reference range of a comparator group
with a more desired immune function (e.g. from values in
bottle-fed infants to those in breast-fed infants). Evidently,
this framework does not neglect the need to consider the
quality of individual studies and consistency of effects and
to consider that ultimate conclusions must be based on the
totality of evidence. However, working through the logical
steps of the proposed framework as presented in Fig. 4 indi-
cates that selected (combinations of) markers can be used to
reach clear conclusions as to whether an observed modulation
of immune function could be regarded as beneficial within
the functional domains of defence against pathogens and
avoidance or mitigation of allergy. For control of low-grade
metabolic inflammation, this is more difficult as there is a
lack of specific markers linking altered immune function(s)
to clinical relevance in this domain. Clearly, it is possible to
reach conclusions on beneficial effects in situations of insulin
resistance and high blood pressure. However, since these are
only very loosely associated with low-grade inflammation, it
will be challenging to firmly establish whether a concurrent
modulation of (inflammatory) markers is correlated.
Finally, it is important to stipulate that the selection of mar-
kers and the complete approach are geared towards the
assessment of effects on relevant physiological functions of
the immune system or markers indicating benefits or risks at
the group level within the general population. This is clearly
distinct from the use of markers to diagnose or monitor the
progression of disease in individual patients. Moreover, the
evaluation and classification of markers indicated herein are
based on an expert judgement of the authors, partially vali-
dated by discussions at a workshop with a wider group of
experts. Scores and classification may be debated to some
extent and conclusions for individual markers may change
over time as more robust data on the association with relevant
clinical outcomes in the general population become available.
More importantly, the structured stepwise approach that was
followed offers a rationale for selecting markers for future
trials and helps to provide a framework for the interpretation
of outcomes. In fact, a similar stepwise approach may also be
useful to rationalise the selection and interpretation of markers
for other physiological processes that are critical to the main-
tenance of health and well-being in the general population.
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